Platelet Rich Plasma as Monotherapy in Androgenetic Alopecia
DOI:
https://doi.org/10.63682/jns.v14i1S.9224Keywords:
N\AAbstract
Introduction. We aimed to know the effect of PRP therapy in androgenetic alopecia and to determine the degree of response to platelet-Rich plasma in various grades of androgenetic alopecia.
Methods. This hospital-based pilot study was conducted in Department of Dermatology, Venereology and Leprosy Shri Guru Ram Rai Institute of Medical and Health Sciences, Patel Nagar, Dehradun during November 2014 to May 2017. Subjects with in the age 18-40 years, under Hamilton-Norwood classification 1-4 for male pattern baldness, Ludwig alopecia score 1-2 for female pattern baldness were included in the study. After taking history and general examination and routine blood tests and serology was done in all subjects. PRP was prepared by collecting 20 ml of patient’s venous blood in Sodium citrate vial and centrifuged at 3000 rpm for 15 minutes to obtain plasma, buffy coat and RBC layer. The plasma and buffy coat were aspirated and again centrifuged at 2000 RPM for next 10 minutes to further obtain reduced volume of PRP by ¼ settled at the bottom. PRP was activated by addition of calcium gluconate by 9:1 and injected by insulin syringes two units intradermal 1 cm apart at 0.5 cm depth in alopecic area monthly for 6 months.
Results.The mean of hair pull test before study was 5.44 ± 2.75 which reduced to 0.38±0.62 after completion of 6 sessions. Further post hoc analysis showed significant improvement was noted between hair pull test results before therapy and at 3 months (p<0.0001) and at 6 months (p=0.007). The mean hair density before treatment was 96.54±24.99 which increased to 106.92±28.04/cm2. Further post hoc analysis showed significant improvement was noted between hair density results before therapy and at 3 months (p<0.0001) and at 6 months (p<0.0001). Also, significant improvement was noted at 6 months of follow up compared to 3 months of follow up (p<0.0001).
Conclusion. Role of PRP in androgenetic alopecia is an emerging treatment but there is lack of data about its efficacy. We lack a comparative group with placebo or with some other treatment like PRP with minoxidil or finasteride.
Downloads
Metrics
References
Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. Anaisbrasileiros de dermatologia. 2015 Aug;90(4):529-43.
Jang WS, Son IP, Yeo IK, et al. The annual changes of clinical manifestation of androgenetic alopecia clinic in Korean males and females: a outpatient-based study. Ann Dermatol. 2013;25:181–188.
Yang CC, Hsieh FN, Lin LY, et al. Higher body mass index is associated with greater severity of alopecia in men with male-pattern androgenetic alopecia in Taiwan: a cross-sectional study. J Am AcadDermatol. 2014;70:297–302.
Di Loreto C, La Marra F, Mazzon G, et al. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. PLoS One. 2014;9:e100237.
Rossi, A., Anzalone, A., Fortuna, M. C., Caro, G., Garelli, V., Pranteda, G., & Carlesimo, M. (2016). Multi‐therapies in androgenetic alopecia: Review and clinical experiences. Dermatologic Therapy, 29( 6), 424– 432.
Katzer T, Leite Junior A, Beck R, da Silva C. Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti‐androgens. Dermatologic therapy. 2019 Sep;32(5):e13059.
De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J. Endotext, MDText. com. Inc., South Dartmouth (MA). 2000.
McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenic alopecia.Skin Therapy Lett. 2012 Jun;17(6):1-4.
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP?. Implant dentistry. 2001 Dec 1;10(4):225-8.
Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. International journal of women's dermatology. 2019 Feb 1;5(1):46-51.
Kachhawa D, Vats G, Sonare D, Rao P, Khuraiya S, Kataiya R. A spilt head study of efficacy of placebo versus platelet-rich plasma injections in the treatment of androgenic alopecia.Journal of cutaneous and aesthetic surgery. 2017 Apr;10(2):86.
Schiavone G, Raskovic D, GrecoJ, Abeni D. Platelet rich plasma for androgenetic alopecia: A pilot study. DermatolSurg 2014;40:1010 9.
Betsi EE, Germain E, Kalbermatten DF, Tremp M, Emmenegger V. Platelet-rich plasma injection is effective and safe for the treatment of alopecia. Eur J PlastSurg 2013; 36:407-12.
Grover S. A study of patterns of androgenetic alopecia in men: An Indian perspective. Br J Dermatol 2005; 152:572-4.
Sehgal VN, Kak R, Aggarwal A, Srivastava G, Rajput P. Male pattern androgenetic alopecia in an Indian context: A perspective study. J EurAcadDermatolVenereol 2007; 21:473-9.
Gkini MA, KouskoukisAE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J CutanAesthetSurg 2014; 7:213-9.
Khatu SS, More YE, GokhaleNR, ChavhanDC, Bendsure N. Platelet rich plasma in androgenic alopecia: Myth or an effective tool. J CutanAesthetSurg 2014; 7:107-10.
Kang JS, Zheng Z, Choi MJ, Lee SH, Kim DY, Cho SB.The effect of CD34+cell‑containing autologous platelet‑rich plasma injection on pattern hair loss: A preliminary study. J EurAcadDermatolVenereol 2014; 28:72‑9.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
